Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 753 results for adult social

  1. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

    Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA192

  2. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

    HealthTech guidance
    Last updated
    3 February 2026
    View recommendations

    Sections for HTG736

  3. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

    Medtech innovation briefing
    Published
    20 April 2017

  5. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)

    Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.

    Technology appraisal guidance
    Published
    29 April 2026
    View recommendations

    Sections for TA1147

  6. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA160

  7. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTG10889 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

    Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

    Technology appraisal guidance
    Published
    25 November 2009
    View recommendations

    Sections for TA184

  9. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Antimicrobial resistance guidance
    Published
    17 August 2022
    View recommendations

    Sections for AMR1

  10. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA412

  11. How the faecal immunochemical test is changing bowel cancer referrals and what it tells us about the power of NICE guidance

    Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 unnecessary urgent referrals a year while keeping cancer detection rates stable.

    News
    Last updated
    18 June 2026

  12. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

    Technology appraisal guidance
    Published
    20 April 2023
    View recommendations

    Sections for TA880

  13. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

    Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    25 March 2014
    View recommendations

    Sections for TA307

  14. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

    Medtech innovation briefing
    Published
    14 September 2016

  15. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTG674)

    Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.

    HealthTech guidance
    Published
    4 May 2023
    View recommendations

    Sections for HTG674